 Skye Bioscience Inc OTCQB:SKYE said it has completed dosing of SBI-100 Ophthalmic Emulsion OE in the first cohort of healthy participants in the single ascending dose SAD part of its Phase 1 study being conducted by CMAX Clinical Research in Adelaide, Australia. This first-in-human Phase 1 trial is a significant milestone for Skye and SBI-100 Ophthalmic Emulsion. 